Hypothesis

Podocyte-specific p16INK4a activation triggers a Notch1‑YAP/TAZ mechanotransduction axis that drives podocyte dedifferentiation and apoptosis independent of tubular NF‑κB signaling.

Rationale

Recent work shows p16INK4a promotes tubular senescence via CDK4/6 inhibition and NF‑κB‑driven SASP [1][2]. However, glomerular injury, not tubular loss, correlates best with CKD progression [1]. Podocytes are post‑mitotic and highly mechanosensitive; loss of cytoskeletal integrity activates YAP/TAZ, which can cooperate with Notch1 to induce epithelial‑to‑mesenchymal transition‑like programs [5]. We propose that p16INK4a, by maintaining Rb hypophosphorylation, alters actin‑myosin tension through dysregulation of cyclin D‑CDK4/6 substrates that also regulate focal adhesion kinases, thereby increasing nuclear YAP/TAZ. Elevated YAP/TAZ then synergizes with Notch1 intracellular domain (NICD) to upregulate Hes1 and podocyte injury markers (WT1 downregulation, desmin upregulation), culminating in apoptosis via Bax/caspase‑3 activation.

Predictions

1. In podocyte‑specific p16INK4a knockout mice subjected to ischemia‑reperfusion or cisplatin, Notch1 NICD and nuclear YAP/TAZ levels will remain baseline despite tubular NF‑κB activation.
2. These mice will exhibit reduced albuminuria, preserved podocyte foot‑process width (electron microscopy), and lower desmin+/WT1‑ podocytes compared with wild‑type controls.
3. Pharmacologic inhibition of YAP (verteporfin) or Notch (γ‑secretase inhibitor) will phenocopy the protective effect of podocyte p16INK4a loss.
4. Conversely, podocyte‑specific overexpression of p16INK4a will increase Notch1‑YAP/TAZ co‑localization, accelerate podocyte detachment, and worsen GFR decline even when tubular NF‑κB is blocked.

Experimental Approach

• Generate Podocin‑Cre; p16INK4a^fl/fl mice and validate podocyte‑specific deletion by PCR and immunostaining.
• Subject mice to unilateral ischemia‑reperfusion (30 min) or cisplatin (20 mg/kg) and collect kidneys at 24h, 72h, and 7d.
• Measure serum creatinine/BUN, urinary albumin/creatinine ratio.
• Perform immunostaining for p16INK4a, NICD, YAP, phospho‑YAP (Ser127), desmin, WT1, cleaved caspase‑3.
• Quantify nuclear vs cytoplasmic YAP/TAZ by imaging flow cytometry.
• Assess tubular NGAL and NF‑κB p-p65 to confirm tubular injury proceeds.
• In parallel, treat wild‑type mice with verteporfin (50 mg/kg i.p.) or DAPT (10 mg/kg) and compare outcomes.
• Include rescue experiments: podocyte‑specific NICD overexpression in p16INK4a KO to test if Notch reactivation restores injury.

Potential Pitfalls

Compensatory upregulation of p21 may obscure phenotypes; double podocyte‑specific p16INK4a/p21 KO may be required. Off‑target effects of senolytics on podocytes need control with vehicle. Ensuring Cre specificity is critical; use Rosa26‑tdTomato reporter to validate.

This hypothesis links cell‑cycle regulators to mechanotransductive pathways in glomeruli, offering a testable mechanism for podocyte loss that extends beyond tubular‑centric models.